Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00561093 · ClinicalTrials.gov registry record · Phase 3
Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients
A Phase 3 study, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 93
- Enrollment target
NCT00561093: Completed Phase 3 study, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
NCT00561093 is a Phase 3 study that has completed, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The registered enrollment target is 93 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00561093, a Phase 3 study, has completed, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 93 participants
- Enrollment target
Study Summary
Study of efficiency and safety of oral nutritional supplements with anti-inflammatory and antioxidative properties combined with an appetite stimulant with anti-inflammatory properties (pentoxiphylline) in treatment of malnutrition-inflammation-cachexia syndrome in maintenance hemodialysis patients
Interventions
- DRUG pentoxiphylline
- DIETARY_SUPPLEMENT Nepro
- DIETARY_SUPPLEMENT anti-inflammatory module (similar to Oxepa)
- DRUG Placebo pill imitating pentoxiphylline
- DIETARY_SUPPLEMENT Placebo to imitate Nepro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2008-02 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
What the finished NCT00561093 record still lists
NCT00561093 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 5 interventions - of which pentoxiphylline is the first listed.
NCT00561093 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00561093 about?
NCT00561093 is a clinical study titled "Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients". Study of efficiency and safety of oral nutritional supplements with anti-inflammatory and antioxidative properties combined with an appetite stimulant with anti-inflammatory properties (pentoxiphylline) in treatment of malnutrition-inflammation-cachexia syndrome in maintenance hemodialysis patients
What is the current status of trial NCT00561093?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 93 participants. The study started on 2008-02. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00561093?
The interventions under investigation include: pentoxiphylline (DRUG), Nepro (DIETARY_SUPPLEMENT), anti-inflammatory module (similar to Oxepa) (DIETARY_SUPPLEMENT), Placebo pill imitating pentoxiphylline (DRUG), Placebo to imitate Nepro (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00561093?
This trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00561093's enrollment target sits among peer trials
93 1722nd of 2000 higher than 278 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia